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ABSTRACT  
 
   
The research question explored in this thesis is how CRISPR mediated editing is 
influenced by artificially opened chromatin in cells. Closed chromatin poses a barrier to Cas9 
binding and editing at target genes. Synthetic pioneer factors (PFs) are a promising new 
approach to artificially open condensed heterochromatin allowing greater access of target 
DNA to Cas9. The Haynes lab has constructed fusions of enzymatic chromatin-modifying 
domains designed to remodel chromatin and increase Cas9 editing efficiency. With a library 
of PFs available, this research focuses on analyzing the behavior of Cas9 in chromatin that 
has been artificially opened by PFs. The types and frequency of INDELs (insertions & 
deletions) were determined after non-homologous end joining (NHEJ) in PF and Cas9-
treated cells using quantitative Sanger sequencing and Synthego’s ICE software. 
Furthermore, NOME-seq analysis was carried out to map nucleosome position in PF and 
Cas9 treated cells. Although this experiment was unsuccessful, the heat map generated with 
data obtained from Synthego ICE predicts a possible presence of nucleosome in the vicinity 
suggesting that perhaps a fully open chromatin state was not achieved. Linear Regression 
analysis with certain assumptions confirms that with the increase in distance downstream of 
cut-site, the editing frequency decreases exponentially. Nevertheless, further experimental 
work should be carried out to investigate this hypothesis.   
  
  ii 
TABLE OF CONTENTS  
          Page 
CHAPTER 
1 INTRODUCTION  .............................................................................................................  1  
Genome Engineering and Application ........................................................................ 1 
CRISPR/Cas9 gene editing tool ................................................................................... 2 
Explanation of chromatin structure ............................................................................. 4 
Solutions to make CRISPR / Cas9 editing better ..................................................... 5 
Pioneer factors and their functions .............................................................................. 6 
2 MATERIALS AND METHODS ...................................................................................... 8  
Experimental procedure for ICE ................................................................................. 8 
Nuclesome Occupancy and MEthylome Seqeuncing ............................................ 11 
3 RESULTS  ............................................................................................................................  22  
MEthylviewer Software ................................................................................................ 23 
Synthego ICE software ................................................................................................. 31 
MS Excel regression analysis ....................................................................................... 40 
4 DISCUSSION  ....................................................................................................................  46  
REFERENCES  ....................................................................................................................................... 49 
 
 
 
  
 
  1 
CHAPTER 1 
INTRODUCTION 
1. Genome engineering and its applications  
Genome Engineering is the targeted modification of genome, its structure or its outputs 
(transcripts) (5). The process is widely researched in biomedical, medical and biotechnology 
fields (25).  Of the many applications in these fields, CRISPR can be used for gene surgery by 
correcting genetic mutations in human cells, drug development by creating synthetic circuits 
in cells to generate drug precursors, cost efficient biofuel production through synthetic 
metabolic pathways of ethanol production, conferring disease resistance in agricultural crops, 
creation of synthetic biological products - derived materials such as for drug development, 
and, to observe genetic variation on phenotypes or biological functions (to mimic a disease) 
in cellular and animal models (25).  
With the advent of induced pluripotent stem cell (iPSC) technology, CRISPR gene editing has 
been used in patient-derived iPSCs to create cellular disease models (26). Cellular disease 
models of hemophilia, sickle cell disease, beta thalassemia, Duchenne and Becker muscular 
dystrophy, Down’s syndrome etc. have been generated in a dish using iPSCs (27-31). These 
disease models can be used to test for gene editing in patients suffering from specific genetic 
diseases or they can be used for drug discovery against these diseases (32). In case of former, 
research has been conducted to test the effectivity of CRISPR / Cas9 editing in patient-derived 
iPSCs. For instance, gene therapy for hemophilia has been exhibited by transplanting corrected 
cells in mouse models (27). Cancer research has led to the creation of CAR T cells (chimeric 
antigen receptor T cells) using CRISPR / Cas9 editing technique to recognize cancer cells. 
CART cells are thought to effective against lymphoma, leukemia and melanoma (33-35).  
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2. CRISPR / Cas9: a gene editing tool 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a powerful tool that 
uses an engineered enzymes (Cas9) to perform “gene surgery,” where DNA is cut and edited 
(3) to correct disease-related mutations in living cells. The CRISPR system is a defense 
mechanism of bacterial cells against viral attacks. The CRIPSR system have two major 
components including a guide RNA (gRNA) (GPS) which is specific to the target site and a 
non-specific molecular scissors, CRISPR associated endonuclease protein (Cas9) (4) (figure 1). 
The gRNA acts as GPS and guides the Cas9 molecular scissors to cut at a specific target site.  
 
 
 
 
 
 
 
 
 
In recent years, this bacterial immune system has become a popular research interest as gene 
editing tool for eukaryotic cells.  Scientists discovered that a change in gRNA can easily help 
Cas9 edit eukaryotic genome. There are usually two outcomes of gene editing: the site-specific 
DNA double-strand breaks (DSBs), which result in homology-dependent repair (HDR) 
and/or error-prone non-homologous end-joining (NHEJ) (figure 2). In HDR, the cellular 
machinery uses a donor DNA template to efficiently correct the target DNA at the site of 
Figure 1: CRISPR / Cas9 system (4) 
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editing. In NHEJ, the cellular machinery ineffectively repairs the target DNA (at cut-site) and 
introduce small INDELs (insertions or deletions of bases) (5).  
However, as easy as it seems, the eukaryotic chromosome has a complex structure with 
nucleosomes and other protein factors affecting the direct accessibility of gene for editing. 
Researchers have realized that CRISPR-mediated editing is significantly affected by the 
chromatin state and increased editing activity in euchromatin state is achieved (6).  
 
 
 
 
Figure 2: outcomes of CRISPR mediated editing (5) 
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3. Explanation of chromatin structure 
The structure of chromatin comprises eukaryotic DNA and histone molecules. The basic unit 
is a nucleosome which consists of a 147-base pair of DNA wrapped around an octamer of 
histone molecules (1) (figure 3). This structure of chromatin allows DNA to be packaged in 
to smaller volumes to be easily carried in cell’s nucleus. It also increases the strength of DNA, 
avoiding breakage during continuous cycles of mitosis and meiosis. The structure of chromatin 
plays a fundamental role in expression of genes - regions of eukaryotic genome. DNA related 
activities such as transcription, DNA recombination and repair etc., depend on the structure 
of this chromatin (2).  
The chromatin is usually found in either of the two states. Chromatin may be in a condensed 
form known as the “heterochromatin” state or in a less condensed “euchromatin” state. In 
heterochromatin state, the genes are unexpressed since their accessibility to cellular machinery 
is blocked by presence of nucleosome whereas in a euchromatin state, certain genes are found 
in a loose state so that these are easily accessible by cellular machinery for expression. Thus, 
the presence of nucleosome in a chromatin structure holds significance in gene expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Structure of a chromatin (7) 
euchromatin
n 
heterochromatin 
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4. Solutions to make CRISPR / Cas9 editing better 
Mammalian cells have the endogenous ability to form a heterochromatin structure around 
transgenes. The heterochromatin structure hinders the ability of Cas9 nuclease to access target 
genes (8). CRISPR / Cas9 technology also needs improvement in terms of specificity, 
efficiency and spatiotemporal control (36).  
One of the potential solutions to improve CRISPR mediated editing is gRNA optimization 
(37, 38). gRNA designs are now chosen based on computational predictions to maximize 
editing and minimize off-target effects (46). Research suggested the use of short length sgRNA 
(about 16-18 bp) or the inclusion of two Guanine (G’s) residues at the end of the gRNA 
sequence to increase sensitivity to mismatch (39, 40).  
The nuclease itself has been subjected to various improvements over the years. Different 
CRISPR systems have been discovered in different bacterial cells. For instance, Cas9, still a 
widely used type 2 CRISPR system was discovered in Streptococcus family. It makes a blunt 
double stranded break in its target DNA which can be repaired by cell’s endogenous NHEJ 
repair mechanism or via HDR if a donor template is present. However, Cas9 is vulnerable to 
off-target effects. Variants of Cas9 include nickase Cas9 (nCas9) and nuclease-deactivated 
Cas9 (dCas9). Cas9 has two nuclease domains, mutating one of them creates nCas9 that only 
cleaves one of the double stranded target DNA (41, 42). However, for dCAs9 both nuclease 
domains are mutated such that dCas9 can effectively bind to the target DNA but is unable to 
cleave it. This is extremely useful in epigenetic regulation when dCSA9 is fused to a molecule 
(43, 44). Cas12 is another nuclease discovered in a different bacterial species including 
Francisella novicida. It makes staggered double stranded breaks in target DNA region. It is 
widely popular for epigenetic editing and detection of small DNA molecules. Cas12 processes 
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its own gRNAs, hence it is very useful for multiplex editing (45). Cas13 is a type 6 CRISPR 
system that only targets RNA. Cas13 has exhibited potential for RNA knockdown and 
subsequently affecting gene expression without changing gene sequence.  
A potential solution for epigenetic regulation in order to increase accessibility to target DNA 
is to recruit activators (8). The function of these activators is to reverse the epigenetic silencing, 
mediated through promoter methylation, histone methylation or activity or Polycomb 
Repressor Complex (PRC). The activators, known as pioneer factors, can be a part of 
transgene sequence added to the endogenous DNA, a fusion protein that is recruited to the 
target sequence or fusion proteins that target these activator domains.    
5. Pioneer Factors (PFs) and their function 
Pioneer factors are a are unique class of transcriptional activators that can access DNA within 
closed chromatin. These are a promising new approach to artificially open condensed 
heterochromatin allowing greater access of target DNA to Cas9.  The Haynes lab has 
constructed fusions of enzymatic chromatin-modifying domains designed to remodel 
chromatin and increase Cas9 editing efficiency (figure 4).   
Figure 4: PFs allow chromatin access to Cas9 endonuclease 
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Activators or Pioneer factors can be remodelers that shift, remove or exchange nucleosome 
or displace linker histones. These may carry out enzymatic activity on nucleosome or recruit 
other catalytic co-factors for chromatin remodeling. These may belong to any of the six 
defined categories including the transcriptional activation group, the histone acetylation group, 
the H3 methyltransferase group, the H3 methyltransferase group, chromatin remodelers and 
pioneer factors (8). The thesis concerns with 5 of these activators namely ATF, MYB, 
SMARCA, KAT2B, KMT2A.  
ATF and KAT2B belong to the histone acetylation groups. These proteins acetylate H3K27. 
MYB transcriptional activation domain belongs to the transcriptional activation group which 
recruits Polymerase II and p300 / CBP. This protein does not regulate gene itself instead it 
recruits other factors to activate transcription. SMARCA is a chromatin remodeler which is 
known to shift nucleosome positions at target regions via an ATP-dependent reaction. 
KMT2A belongs to the H3 methyltransferase group. Most of these proteins are also involved 
in displacing PRC complexes from endogenous genes (8).  
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CHAPTER 2 
MATERIALS AND METHODS 
1. Experimental procedure for ICE  
The Haynes lab used a doxycycline-inducible system that induces PRC2 heterochromatin at a 
luciferase reporter in HEK 293 cells to compare the activities of the pioneer factors (figure 5).  
a. Closed chromatin: Doxycycline represses TetR allowing expression of Gal4-EED 
which recruits Polycomb proteins (RBAP, SUZ12, EZH2) that silence the luciferase 
reporter gene.  
b. Open chromatin: Gal4-EED is silenced by TetR, which prevents Polycomb 
accumulation and allows expression of luciferase. 
Cells with closed chromatin were treated with Pioneer Factors and Cas9. Two vectors were 
designed, one containing the pioneer factor region and the other containing the Cas9 and its 
gRNA. The HEK 293 cells were co-transfected with vectors. These cells were then sorted 
through flow cytometry. Parameters were assigned on flow cytometer to obtain accurate 
results. The DNA of cells sorted was subsequently extracted and the Cas9 target region was 
amplified using PCR technique. The amplified region was sequenced based on Sanger 
sequencing techniques. The sequencing results were used for in-silico analysis in Synthego’s 
ICE software. Synthego’s ICE software quantified the sequencing results and provided 
detailed analysis of the INDELs generated by the CRISPR mediated editing on pioneer factor 
treated cells.  
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a. Construction of Plasmids 
Plasmid vectors for Cas9 and Pioneer factors were constructed as described in Barrett 2018 
(8). A mammalian expression vector 14 (MV14) was constructed to express Gal4-mcherry-
AAP proteins. AAP proteins are the pioneer factors. The MV13 vector was initially 
constructed by fusing mCherry into MV10 vector (9). Next a gBlock fragment and digestion 
sites were added to MV14. Lastly, the AAP proteins were cloned in to MV14 vector. A 
pX330A_dCas9-1 x 4 plasmid (a gift from Takashi Yamamoto, Addgene plasmid #63598) was 
modified to include synthetic gRNA (sgRNA), and a gene fragment coding for MYB TAD 
(10) and mCherry. sgRNA was designed in-silico on CRISPR design tool at crispr.mit.edu.  
The sgRNA was added to the plasmid using the Cong et al. protocol (11).  
 
Figure 5:  Experimental Procedure for Synthego ICE INDEL analysis 
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b. Cell culture and transfection 
Cell culture and transfections were carried out using the protocol described in Barrett et al (8).  
Luc14 and Gal4-EED/luc HEK 293 cells were cultured at 37 °C in a 5% CO2 incubator by 
adding GIBCO DMEM, 10% Fetal Bovine Serum, 1% penicillin streptomycin. Doxycycline 
drug was added to Gal4-EED/luc cells for 2 days. After removal of dox, the Gal4-EED/luc 
cells were cultured again for 4 days before they were ready for transfection. Both Luc14 and 
Gal4-EED/luc cells were transfected with 1 ug of plasmid, 3 uL of lipofectamine, and 1 uL 
Plus Reagent. These cells were analyzed 72 hours after post transfection.  
c. Flowcytometry 
Flow Cytometry was carried out using the protocol described in Barett et. al (8). The 
experiment was carried out on BD Accuri C6 flow cytometer (675 nm LP filter) using CFlow 
Plus software. Red and green signals were detected. FlowJo 10.5.3 software was used for in-
silico analysis. 10,000 live cells were analyzed (gated by forward and side scatter) and median 
fluorescence was calculated.  
d. Synthego ICE software  
Sequences of Cas9 target sites from Cas9 and pioneer factor treated Luc14 and Gal4-EED 
HEK 293 cells were uploaded on the ICE software. ICE software is an online, user friendly 
software operated by Synthego.  Luc14 cell sequence not transfected with Cas9 and pioneer 
factor plasmids was used as control or wild type. The sgRNA sequence was also uploaded to 
the software for analysis. Lastly, sequences of Gal4-EED HEK 293 cells treated with Cas9 
and pioneer factors were uploaded in a “sample by sample” method.  
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2. Nucleosome Occupancy and MEthylome Sequencing (NOME-Seq)  
Nucleosome Occupancy and MEthylome Sequencing (NOME-Seq) is a technique to 
determine the relationship between nucleosome position, transcription factor binding and 
methylation status of DNA. Epigenetics and chromatin configuration play a major role in Cas9 
binding and its editing at target sites. ActiveMotif’s Nucleosome Occupancy and MEthylome 
Sequencing (NOME-Seq) kit allows to determine the nucleosome position based on DNA’s 
methylation status. It can also be used to determine the endogenous methylation status of 
DNA at CpG islands (12).  
The figure below summarizes the process of NOME-sequencing (figure 6). In general, 
formaldehyde is used to fix cells and cross-link protein-DNA interaction. This way the 
nucleosome positions are retained. The chromatin is then sheared through sonicated and as 
large as more than 1 kb fragments are obtained.  The fragments are subsequently treated with 
GpC DNA methyltransferase. This allows for GpC regions, not blocked by nucleosome or 
transcription factors, in DNA fragments to be artificially methylated. The cross-links of DNA 
fragments are then reversed, to allow access to protein bound DNA regions. The DNA 
fragments are also subjected to treatment with Proteinase K, and RNAse. The DNA fragments 
are purified for bisulfite genomic conversion. In Bisulfite conversion DNA fragments are 
treated with sodium bisulfite which deaminates unmethylated cytosine converting them to 
uracil residues. These fragments are then PCR amplified using bisulfite specific primers. The 
fragments are sequenced, and methylation status analysis is carried out using in-silico 
MEthylviewer software. The software differentiates between unmethylated (white circles) and 
methylated cytosine (black circle) residues. This allows to determine the position of 
nucleosome spanning approximately a 147 bp region of unmethylated cytosine residues.  
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Figure 6:  NOME-Seq protocol (12) 
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a. Timeline for ActiveMotif’s NOME-Seq kit  
The Active Motif’s NOME-Seq kit protocol is a 3-day experimental analysis of cells that have 
been cultured, transfected and passaged. We carried out the protocol over a period of 3 weeks, 
using 2 kits. The idea was to carry out the process 3 times, once as a test run to accommodate 
errors, second on control cells of Luc 14 and Gal4-EED not transfected with Cas9 and pioneer 
factor treatment, and lastly on cells transfected with Cas9 and pioneer factors. For pioneer 
factor transfection, only those plasmids were chosen which exhibited high editing frequency 
on Synthego’s ICE software. These include ATF, SMARCA4, and MYB. Each kit contains 
sufficient reagents for 17 reactions. It was decided that 2 replicates in test run for each of Luc 
14 and Gal 4 sample, 2 replicates for each of the control samples, and 3 replicates for each 
pioneer factor treated samples will be analyzed. The transfection of pioneer factors was carried 
out simultaneously while the NOME-seq experiment was conducted for control samples. The 
timeline for the experimental procedure is given below.  
• Luc 14 (x2), Gal 4 (x2) (test run: 4 samples) 
• Day 1:  thaw  
• Day 3: Passage 
• Day 4-5: Day 1 of kit  
• Day 6: Day 2  
• Day 7: Day 3  
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• Day 8: Sequencing result 
• Luc 14 (x2), Gal4 (x2) (control: 4 samples, already thawed and passaged) 
• Day 9: Day 1 of kit   
• Day 10: Day 2 of kit  
• Day 11: Day 3 of kit  
• Day 16: Sequencing results 
• GAL4– pioneer factor (each x3, altogether 9 samples) 
• Day 1: Thaw 
• Day 3: Passage and silence  
• Day 5: Remove dox 
• Day 9: Transfect 
• Day 10: puromycin selection 
• Day 12: Day 1 of kit  
• Day 13: Day 2 of kit  
• Day 14: Day 3 of kit  
• Day 16: Sequencing results  
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b. NOME-sequencing kit protocol 
The ActiveMotif’s NOME-seq kit is a 3-day protocol that consists of buffer preparation for 
each day and various experimental procedures. The reagents provided in the kit are enough 
for 10 enzymatic reactions and 10 control reactions. Additional materials, including cell 
culture, PCR and sequencing reagents, are required. The manual that accompanies the kit 
provides details on buffer preparation. It also gives details of the number of cells required for 
each reaction. The manual recommends using 1.5 x 107 cells from a 15 cm tissue culture plate 
for all 20 reactions. It also provides explanations of errors encountered during the 
experimental procedure.  
i. Day 1 
Buffers for most of the procedures, are prepared according to the quantities required and the 
details provided in the manual. These buffers include fixation solution, 1x PBS solution, 
glycine stop-fix solution, 1x NE solution, cell scraping solution, lysis buffer, 100 mM DTT, 
10 x reaction buffer AM2, 100x AdoMet, GpC Methyltransferase enzyme, and stop solution 
AM2. Day 1 lasts for approximately 6-8 hours and can be stopped after cell fixation or 
sonication. Day 1 consists of cell fixation, chromatin sonication to more than 1 kb fragments, 
GpC methyltransferase enzymatic reaction, reversal of cross-links.  
ii. Day 2 
Day 2 lasted for approximately 7-8 hours. The buffers prepared for Day 2 include conversion 
buffer and hydroquinone. On Day 2 fragments are treated with RNAse A and Proteinase K 
treatment, purified and bisulfite genomic conversion of these fragments are carried out.  
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iii. Day 3  
Day 3 lasts for 3-4 hours. It consists of DNA desulfonation and DNA purification of bisulfite 
converted DNA, PCR amplification with bisulfite specific PCR primers, DNA purification 
and subsequently Sanger sequencing.  
c. Cell fixation 
For each 15 cm plates, the medium was poured off and 20 ml fixation solution is added. The 
plates were shaken for 10 minutes at room temperature. After pouring off the fixation 
solution, cells were washed by 10 ml ice-cold 1x PBS, rocked for 5 minutes and the PBS 
solution was poured off. This was followed by addition of 10 ml glycine stop-fix solution (to 
stop fixation), rocking cells for 5 mins and pouring off stop-fix solution. Cells were washed 
again with 1x PBS. An ice-cold, cell scarping solution was added to plates and the cells were 
scraped off using rubber policeman while keeping plates at an angle. 1 ml of cells were 
transferred to a conical tube and centrifuged at 4 °C for 10 minutes at 2500 rpm. The 
supernatant was removed, and pellet discarded.  
d. Sonication 
Pellet was thawed in 1 ml ice-cold lysis buffer. The cells were then transferred to a 1.5 ml 
eppendorf tube and centrifuged for at 4 °C for 10 minutes at 5000 rpm. The supernatant was 
discarded, and pelleted nuclei are resuspended in 1 ml of 1X NE wash buffer. The cells were 
again centrifuged at 4 °C for 10 minutes at 5000 rpm. The supernatant was discarded, and 
pellet was resuspended in 1 ml of 1x NE buffer and placed on ice. Using the number of cells 
fixed per plate, volume of suspension required to obtain 750,000 is calculated. This amount is 
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sufficient for two NOME-seq reactions. This volume containing 750,000 cells was aliquoted 
in a 1.5 ml eppendorf tube and centrifuged at 4 °C for 10 minutes at 5000 rpm. The 
supernatant was removed, and pellet was resuspended in 300 ul of 1x reaction buffer AM2. 
The nuclei were sonicated to a greater than 1 kb chromatin size using a sonicator. The 
sonicator was set to suggested settings, sonicator on ice with a 25% amplitude, 30 seconds on 
time and 30 seconds off time for a total of 3 minutes. The tubes were spinned gently.  
e. Methyltransferase reaction 
Methyltransferase reactions were set up in a 1.5 ml eppendorf tube and a negative control 
reaction was also set up to determine the endogenous methylation profile. The following table 
shows the reagents and volume required for both reactions. The reactions were incubated for 
4 hours at 37 °C and at each hour 1 ul of 100x AdoMet was added to each reaction. The tubes 
were mixed by inverting them 4-5 times. 50 ul of stop solution AM2 was added at the final 
hour to stop the reaction. The cross links were then reversed by placing tubes on 65 °C 
overnight.  
Reagents Sample (uL) Negative control (uL) 
dH20 32 37 
10X Reaction buffer AM2 5 5 
100 mM DTT 5 5 
100x AdoMet 3 3 
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Fragmented chromatin 100 100 
GpC methyltransferase enzyme 5 - 
Total 150 150 
 
f. Proteinase K treatment and DNA purification 
The tubes were spun briefly at room temperature. These were incubated at room temperature 
for 30 minutes after addition of 4 ul of RNAse A.  These were further incubated for I hour at 
50 °C after adding 6 ul Proteinase K. The reactions were transferred to a new tube and 1050 
ul of DNA purification binding buffer was added. If needed pH was adjusted by adding 3M 
sodium acetate. This was followed by setting up DNA purification columns in collection tubes. 
750 ul of samples were added (in batches if needed) and centrifuged at 14,000 rpm for 1 
minute. The flow-through was discarded. The samples were washed with 750 ul of DNA 
purification buffer and centrifuged at 14,000 rpm for 1 minute. The flow-through was 
discarded. The samples were centrifuged for an additional 2 minutes at 14,000 rpm to remove 
residual wash buffer. The column was transferred to a new eppendorf tube. The samples were 
then eluted in 30 ul of DNA elution buffer and incubated at room temperature for a minute 
before being centrifuged at 14,000 rpm for 1 minute.  
g. Bisulfite conversion  
Following DNA quantification, volume of DNA required for each bisulfite reaction was 
calculated. In general, about 500 ng to 2 ug of DNA is required in bisulfite conversion and up 
  19 
to 13 ul of DNA can be added to the reaction. The volume was adjusted with water if needed. 
The table below shows the quantity of reagents added to sample and negative control. The 
tubes were placed in a thermocycler set to an initial melt of 94 °C for 3 minutes, a 50 °C 
conversion for 5 hours, followed by 4 °C hold.  
Reagents Sample (ul) Negative control (ul) 
Methyltransferase treated DNA _______ ________ 
dH20 _______ ________ 
Hydroquinone 7 120 
Conversion buffer 7 120 
Total 140 140 
 
h. On-column desulfonation and DNA purification 
In a 1.5 ml eppendorf tube, 500 ul of DNA binding buffer and entire conversion reaction for 
each sample was added. The solution was added to DNA purification columns and spun at 
30,000 rpm for 30 minutes. After discarding the flow-through, 200 ul of wash solution was 
added to each column and spun at 30,000 rpm for 30 minutes. The flow-through was discarded 
and 200 ul of desulfonation buffer was added to each column and after 20-minute incubation 
columns were spun at 30,000 rpm for 30 minutes. The flow-through as discarded and columns 
were washed again with wash buffer. The residual buffer was removed by spinning at 10,000 
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rpm for 1 minute. The columns were placed in a new 1.5 ml tube and 50 ul of elution buffer 
was added and columns were incubated for 3 minutes at room temperature.  These were spun 
again at 30,000 rpm for 30 seconds and the eluted solution was collected in a new tube.  
i. PCR reactions 
The DNA fragments were amplified through PCR using the following master mix protocol, 
PCR reactions and thermocycler settings. The PCR reactions were set in 0.2 ml tubes. 
Reagents PCR Master mix (ul) 
dH20 52.5 
Taq Mix 62.5 
Bisulfite specific primer mix 5 
Total 120 
 
Reagents Sample (ul) Negative control (ul) 
Bisulfite-treated 
DNA 
2 2 
PCR master mix 48 48 
Total volume 50 50 
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The thermocycler is set for 95 °C for 3 minutes, for 45 cycles 95 °C for 30 seconds, 65 °C for 
30 seconds, 72 °C, 72 °C for 4 minutes and 4 °C hold. 
j. DNA purification of PCR amplified DNA 
Following amplification, the DNA fragments were purified and quantified. 250 ul of DNA 
purification binding buffer was added to PCR reactions and adjusted with 3M sodium acetate 
if needed. The mixture was added to DNA purification column and the protocol for DNA 
purification after methyltransferase reaction was repeated. The sequences were then submitted 
for Sanger sequencing.  
k. MEthylviewer 
The Sanger sequencing results are used for image analysis on user-friendly MEthylviewer 
software. The sequences were uploaded in *.ab1 file format or FASTA format. In addition, 
the control reference gene was also uploaded. The sequences can be pre-aligned to reference 
sequence or aligned in the software directly. The resulting images were exported in grid, scale 
and dC conversion maps format.  
3. Statistical regression analysis 
Microsoft Excel software was used to process data for simple linear regression analysis. The 
data from ICE Synthego’s software was used. MS Excel’s Data Analysis tool was used to 
calculate the statistics for linear regression analysis.  
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CHAPTER 3 
RESULTS 
The scope of this thesis was to observe if pioneer factors improved CRISPR mediated editing. 
Following sanger sequencing, the results were subjected to in-silico analysis to determine the 
type and frequency of INDELs (INsertions and DELetions) observed after Cas9 editing and 
how the position of nucleosome affects CRISPR / Cas9 editing.  
The sequencing data obtained from NOME Seq was analyzed using MEthylviewer software. 
This software determines the position of nucleosome in a given sequence based on the 
methylation status of its nucleotides. However, the NOME seq data and its in-silico analysis 
through MEthylviewer did not yield expected results. Subsequently, Synthego’s ICE software 
was employed to observe the types and frequency of INDELs generated through non 
homologous end joining method after cas9 editing for each pioneer factor treatment. The 
result obtained from ICE software was further subjected to data mining in Microsoft Excel to 
generate figures.  These figures explicitly depict the types of INDELs generated for different 
pioneer factor treatment. Additionally, another figure portrays the deletion profile for different 
pioneer factor treatment as a heat map.   
Lastly, the figures generated from ICE data also suggest that there is an underlying relationship 
between the distance from cut site of Cas9 molecule and the editing frequency at each base 
position of the considered sequence. The frequency decreases exponentially as distance 
increases. This relationship could be indicative of the presence of a nucleosome in the vicinity 
of the cut site. Hence a regression analysis using Microsoft Excel’s linear regression tool was 
performed to determine the strength of the relationship and mathematically model it.  
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1. MEthylviewer software 
MEthylviewer is a software used for in-silico analysis of Bisulfite Genomic Sequencing (BGS) 
data. The software queries the methylation status of cytosine residues in a bisulfite converted 
DNA sequence. The software can detect up to as many as four user defined sites including 
CG and GC.  
a. Bisulfite Genomic Sequencing 
Nucleosome Occupancy and Methylome Sequencing kit allows investigation of relationship 
between nucleosome occupancy and DNA methylation status of the region. It involves the 
artificial methylation of GpC dinucleotides via a GpC DNA MethylTransferase (DNMT) 
enzyme. The DNMTs methylate those GpC residues which are not protected by nucleosomes 
or proteins such as transcription factors and hence easily accessible (12).  
Bisulfite genomic sequencing follows DNMT process after DNA extraction. The bisulfite ion 
converts the unmethylated cytosine residues (those protected by nucleosome) into uracil 
(13,14). The BGS process as a result distinguishes between unmethylated and methylated 
cytosine residues and consequently analyzes the position of nucleosome based on the 
methylation status of these cytosine residues. The two processes, namely DNA 
methyltransferase activity and bisulfite genomic sequencing are collectively termed as Methyl 
Accessibility Protocol for individual templates (MAPit) (15-20).  
The manual assessment of a bisulfite converted sequence is very cumbersome since it includes 
manual assessment of every cytosine residue that has been methylated (21). The DNA 
analyzed in this case is usually not subjected to digestion and is queried for artificial 
methylation status in one long molecule. The process subsequently not only requires time and 
extra effort but is vulnerable to human errors. In order to avoid these issues, in-silico software 
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such as MEthylviewer have been programmed which provide an automatic analysis of cytosine 
methylation status. In addition, this software provides the facility of primer designing (22,23) 
and aligning FASTA formatted sequences. The most important feature is that it can easily 
distinguish between artificially methylated GpC residues and endogenously methylated CpG 
residues. Thus, the software provides a comprehensive epigenetic analysis - complex 
interaction of DNA molecule and its associated proteins.  
b. Analysis of NOME Seq data 
Once loaded, the Methylviewer software allows users to analyze the sequence in one of the 
two ways, i.e., through alignment or interactive view. In alignment view the word length and 
minimum alignment scores are decided for FASTA formatted sequences. In interactive view, 
a FASTA formatted sequence (figure 7) can be uploaded for analysis without processing. Both 
these ways require that the reference sequence should be of the same DNA strand which is 
being queried for methylation status. This is in line with the fact that after BGS treatment, the 
sequence of the two strands are no longer complementary, hence the reference or original  
 
>luciferase 
genegctcactcattaggcaccccaggctttacactttatgcttccggctcgtatgttgtgtggaattgtgagcggataacaattt
cacacaggaaacagctatgacatgattacgaattcggatcctctagagtctccgctcggaggacagtactccgctcggaggac
agtactccgctcggaggacagtactccgctcggaggacagtactccgctcggaggacagtactccgacctgcaggcatgcaa
gctcgcccggggatccgactagatctgacttctagagatccggcaaaccccgcccagcgtcttgtcattggcgaattcgaaca
cgcaaatgcagtcggggcggcgcggtccgaggtccacttcgcatattaaggtgacgcgtgtggcctcgaacaccgagcgac
cctgcataagcttgccaccatggaagacgccaaaaacataaagaaaggcccggcgccattctatcctctagaggatggaacc
gctggagagcaactgcataaggctatgaagagatacgccctggttcctggaacaattgcttttacagatgcacatatcgaggtg
aacatcacgtacgcggaatacttcgaaatgtccgttcggttggcagaagctatgaaacgatatgggctgaatacaaatcacaga
atcgtcgtatgcagtgaaaactctcttcaattctttatgccggtgttgggcgcgttatttatcggagttgcagttgcgcccgcgaa
cgacatttataatgaacgtgaattgctcaacagtatgaacatttcgcagcctaccgtagtgtttgtttccaaaaaggggttgcaaa
aaattttgaacgtgcaaaaaaaattaccaataatccagaaaattattatcatggattctaaaacggattaccagggatttcagtc 
 
Figure 7: FASTA format luciferase gene sequence 
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sequence should be of the same strand that is queried. The interactive view allows the original 
bisulfite genomic sequencing file to be in *.txt, *.ab1, and *.scf file formats (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once the analysis option is selected the software requires user to select sites for methylation 
status only. These default settings include CG only, GC only and CG and GC. The default 
settings ensure that artificially methylated sites are viewed as black circles whereas the non-
methylated sites are viewed as white circles. The GC and CG setting allows for methylation 
status analysis in vertebrates where endogenous CG methylated sites have to be identified. In 
addition, the custom button allows user to change default colour setting (figure 9). The default 
settings are: (1) white circles for unmethylated CG, (2) black circles for methylated CG – m5 
CG, (3) white triangles for unmethylated GC, (4) red triangles for methylated GC – G-m5 C, 
and lastly the grey areas in the grid represent the overlapping methylation sites of CG and GC 
(G-m5 CG) which could have been methylated by either endogenously or artificially 
methylated.  
Figure 8: MEthylviewer - Analysis can be carried out in Interactive view 
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c. Image Analysis 
The interactive or alignment view generates a grid like figure that depicts methylation status. 
This grid helps to identify methylation status at individual sites aligned to reference sequence. 
The colour of each cell informs the viewer of the methylation status of cytosine (figure 10). 
As mentioned above, the white cell represents unmethylated CG, GC, and CG and GC sites. 
The black cell represents methylated CG sites. The red cell represents methylated GC sites 
and the grey cells represent overlapping methylation GCG sites.  The orange coloured cells 
represent unaligned sites and the blue coloured cells represent the reference sequence. At any 
time placing a cursor on the cell, tells its methylation status at a particular site (CG, GC, or 
CG and GC). It also informs the user of the methylation site position in accordance with the 
reference sequence. The view tab on the top gives the option to select the “identify 
Figure 9: MEthylviewer – User can customize individual methylation status 
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methylation sites” option. Additionally, the image tab allows to include labels, base positions 
and bisulfite conversion frequencies in the image.  
 
 
 
d. Export Data 
Once the grid image is edited according to requirement, the image can be exported for 
documentation. However, before exporting the image it can be processed to show the base 
positions, include labels and the bisulfite conversion frequencies for detailed analysis. These 
options are available in the “image option” tab (figure 11). Furthermore, a user can save the 
original image or edited one. The image resolution can also be increased to 1000 dpi from 100. 
Once the image is ready, three version be saved including grid image, dC conversion map, and 
/ or image drawn to scale.  
A dC conversion map (figure 12) depicts the bisulfite conversion status of sites that are not 
targeted. The sites where C residue does not lie within the queried sequence is shown as a 
Figure 10: Methylation status of each residue is described by colour of the cell.  
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vertical blue line, whereas the C residue that does lie within the sequence is shown as black 
line for methylated and grey line for unmethylated residues. The dC conversion map can also 
be viewed after selecting the “show dC conversion map” in view tab.  
The image “drawn to scale” represents the methylation status of individual DNMT sites using 
symbols. These sites are spaced in accordance with their position on reference sequence. In 
this image (figure 13) the unconverted cytosine sites are represented by vertical blue lines in 
the image. The overlapping CG and GC sites are represented by grey filled triangles and circles. 
In line with the grid image a white circle represents an unmethylated CG site, a white triangle 
represents an unmethylated GC site and a white circle with overlapping triangle represents the 
overlapping unmethylated GCG site. A black circle represents the methylated CG site and a 
red triangle represent the artificially methylated GC site.  
 
 
 
 
 
Figure 11: MEthylviewer – Grid image can be processed using options available in “image 
options” tab/  
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e. MEthylviewer Expected Results  
The images exported from MEthylviewer software exhibit that NOME sequencing did not 
yield expected results. In grid and scale images, unmethylated CG, GC or GCG sites are not 
observed at all. This suggests that there were no nucleosomes or protein (transcription factors) 
Figure 12: Methylviewer – dC conversion map for each pioneer factor.  
Figure 13: MEthylviewer – Image drawn to scale for each pioneer factor.  
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present in the queried sequence against reference luciferase gene. The grid image (figure ) 
displays a number of  orange cells followed by alternative black, red cells, and grey cells. This 
implies that methylated CG, GC and overlapping GCG sites were observed. No white cells 
were observed in the grid image.  
Similarly, in accordance with the grid image, the scale image also displays orange circles 
followed by blue vertical lines, black circles, red triangles, and grey triangle and circle. This 
proposes the presence of unconverted cytosine residues, endogenously methylated CG 
residues, artificially methylated GC residues, and methylated overlapping GCG residues.  
Lastly, the dC conversion map (appendix 1) also show very low bisulfite genomic conversion 
sequencing. The failure to analyze nucleosome positioning, the two images – grid and scale – 
along with the dC conversion map, may be due to errors in NOME sequencing. Bisulfite 
genomic sequencing may be the reason for absence of unmethylated cytosine residues. The 
expectation was to observe unmethylated GpC residues (white cells, white triangles) for more 
than or equal to 147 bp. This would have suggested the presence of a nucleosome in the 
region. If the residues would have spanned 10-80 bp, then there would have been a presence 
of a protein.  The grid and scale image can however be used to create a profile distinguishing 
between endogenously methylated CG residues (black cells and circles), and artificially 
methylated GC residues (red cells and triangles).  
With the failure of NOME Sequencing analysis, Synthego ICE’s analysis was still carried out 
to determine the effects of non-homologous end joining after pioneer factor and Cas9 
treatment.   
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2. Synthego ICE software  
Following the Cas9 and pioneer factor treatment, the Haynes lab wanted to measure the effects 
of Cas9 editing using PCR and melt curve analysis. However, neither of those techniques 
provided enough resolution to determine INDELs generated after non homologous end 
joining. ICE software designed by Synthego company is a user-friendly online software that 
allows user to analyze the effects of CRISPR mediated editing.   
a. Analysis of Sanger sequencing data 
One of the advantages of ICE software over other techniques or software is that it allows 
sanger sequencing data to be analyzed. Most software or techniques only require NGS data, 
making the entire analysis expensive. Hence ICE software is a cost-effective method to 
measure CRISPR edits. Additionally, ICE software allows user to determine if their CRISPR 
experiment resulted in any knock-outs in the gene considered. ICE software provides a 
knockout score that can be used to determine if the INDELs produced can result in a 
functional knock-out in the gene. This knock-out (KO) score represents a proportion of cell 
with a frameshift mutation or 21+ bp INDEL (24).   
ICE software analyzes sanger sequencing samples of CRISPR experiments through “sample 
by sample” or “batch analysis” methods. In “sample by sample” method five experiments are 
compared at a time, whereas in “batch by batch” analysis approximately 100 experiments can 
be compared at a time. The software’s introductory page (figure 13) requires user to label the 
sample, provide gRNA sequence, add a wild type or reference sequence with *.ab1 file format, 
and the test sample with *.ab1 file format. The ICE software will provide the editing efficiency 
of CRISPR and the INDEL profile for each sample.  
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b. ICE tool results 
Once the analysis is complete, the ICE software generates an overview of results for each 
sample (figure 15). The success of analysis of each sample is represented by a coloured symbol. 
A green checkmark in a circle indicates that the sample was analyzed successfully. A yellow 
check indicates that there were few processing errors that may be adjusted by the software 
automatically. In case the analysis was a failure, a red exclamation point next to the sample 
indicates that. This overview includes the sample name, guide target of each sample sequence 
(since one gRNA was provide, the guide target is same for all samples), the PAM sequence, 
ICE score, R2, and KO-score.  
The sample name is the name of each sample file provided before analysis. The guide target is 
the guide RNA sequence, with PAM, of 17-23 nucleotides provided before the analysis. PAM 
Figure 14: Synthego ICE – Sequences and gRNA are uploaded before analysis  
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is the protospacer adjacent motif sequence for each nuclease. Since ICE is designed for 
SpCas9, the PAM sequence is provided accordingly. ICE score provides the editing efficiency 
of Cas9, i.e., the percentage of pool with non – wild type sequence. It is calculated by 
comparing control trace to edited trace and the potential editing outcomes are fitted to 
observed ones using linear regression. R2 is the Pearson’s correlation coefficient which is 
calculated along with linear regression. The higher the value of R2, the more reliable the ICE 
score. Lastly, KO score helps to determine the presence of functional knock out based on 
frameshift mutation (21 + bp INDEL contribution) in a pool of cells.  Most importantly, the 
ICE software provides bar charts of KO-score and ICE-score for each sample against editing 
efficiency. This helps a user to select the best sample if replicates are present. If a sample has 
been successfully analyzed (green check mark), it can be selected to observe the INDEL 
contribution, distribution and traces. This analysis can be downloaded in a zip folder.  
 
 
 
Figure 15: Synthego ICE – Overview of results 
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c. INDEL contribution and distribution and traces 
ICE software generates three different types of outputs, INDEL contribution, INDEL 
distribution and traces. INDEL contribution (figure 16) lists the inferred type of editing 
observed in a sample or edited pool. This tab gives a detailed explanation of the type of each 
INDEL (whether insertion or deletion), the size of each INDEL (the number of bases), and 
the direction of INDEL (in the left or right direction from the cut – site). The cut-site is 
represented by a dotted black vertical line. An insertion is represented with “N” and a deletion 
with a “-”. On the left side of the sequence, the INDEL is labelled: a +/- associated with a 
number; “+” represents insertion and “-” represents deletion. Additionally, the frequency of 
each type of INDEL is provided. Since each sample corresponds with a different pioneer 
factor treatment, each of these sequences were copied in an excel sheet for further curation. 
The cut-off set for INDEL frequency was 2%. Any INDEL type less than 2% frequency was 
not considered.  
Figure 16: Synthego ICE – INDEL contributions tab  
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In INDEL distribution tab (figure 17), the distribution of the inferred INDELs in an edited 
sample pool is displayed as an INDEL. The frequency of inferred INDELs is plotted in a bar 
against their sizes. Next to the INDEL plot is a discordance plot. This plot displays the level 
of disagreement between the edited samples and its wild-type (unedited) reference in the 
inference window for individual bases. The inference window is the region around the cut-
site. The edited sample is represented in green color while the wild type is represented by 
orange color. The cut-site is represented by a vertical black dotted line. It can be observed that 
discordance between the edited and wild type samples increase right after the cut-site. Before 
the cut-site the signals from these to populations are in harmony.  
 
 
The traces tab (figure 18) shows the Sanger traces for both the edited and wild type samples. 
These traces are measured around binding suites of gRNA provided. The horizontal, black 
line signifies the guide sequence. The horizontal, red line signifies the PAM sequence. The 
Figure 17: Synthego ICE – INDEL distribution 
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dotted vertical black line represents the cut-site. The region after cut shows the base call that 
may be erroneous due to non-homologous end joining type repair.  
 
 
d. Post ICE software analysis 
The INDEL contributions data was copied to Microsoft Excel worksheet for every pioneer 
factor treatment. For each pioneer factor treatment, only the INDEL sequences with a 
frequency of 2% or higher were selected.  
The data was curated and analyzed to observe the trend of INDELs. The data suggests that 
there some common frequently observed INDELs for each of the pioneer factor treatment. 
These INDELs were observed to be found in the vicinity of cut-site. The size of INDELs 
included an insertion of one nucleotide (+1), an insertion of two nucleotides (+2), deletion of 
one nucleotide (-1), and deletion of two nucleotides (-2) (see appendix). Interestingly, there 
was variation observed in the position of these INDELs. In some cases, these 1 or 2 bp 
insertions and deletions were found to be present upstream of cut-site, while in other cases 
Figure 18: Synthego ICE - traces 
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these INDELs were found to be present downstream of cut-site (see figure). There were other 
rare observations of 4, 5, 6, 7 and as many as 20 base pair insertions or deletions. However, 
the frequency of these INDELs was very low, hence these were not considered.  
Given the large data set, a stacked bar chart (figure 19) was generated after some processing 
for pioneer factor SMARCA4, MYB, KAT2B, KMT2A. Additionally, control samples 
including Luc 14 and Gal4 were also considered. These samples represent the open and closed 
chromatin states respectively. These samples were considered based on their high ICE-score, 
KO-score and very common INDELs observed across each of these pioneer factor treated 
samples. The data is shown in the figure below. The stacked bar chart compares the frequency 
of editing observed in control samples (open and closed chromatin states) with pioneer factor 
treated samples. It can be observed that almost all these pioneer factors considered restored 
the editing levels to open chromatin states.  
 
 
 
Figure 19: The most frequent INDELs were counted for each treatment. All pioneer 
factor restored editing to “open chromatin” levels. 
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The ICE software data was then analyzed to observe the deletion profile. A section of the 
unedited sequence was considered including both upstream and downstream regions of cut-
site. Using the uncurated data, we observed the INDEL generated at each base potion of the 
sequence. All sizes and positions of INDELs were accounted for each pioneer factor. The 
sequences for these INDELs were lined up against the unedited controls sequence. For 
individual sizes and positions of INDELs, a table was generated such that a 0 was considered 
if the INDEL was not present at that position and a 1 was added if the INDEL was present. 
The entire row with either 1 or 0 at each base position was then multiplied by the frequency 
of that INDEL. The total frequency of a probability of any INDEL being observed at that 
base position was calculated by adding up the frequencies. These were converted to percentage 
(figure 20).  
Once the percentages were calculated, a heat map (figure 21) was generated to determine the 
deletion profile at each base for each pioneer factor type. This deletion profile, also called a 
heat map suggested the frequency of deletion observed at individual base position when all 
sizes of INDELs were accounted for. The heat map was colour coded with red representing 
high probability and blue representing low probability. The heat map shows that as the 
distance in base position increased from cut-site, the probability of finding a deletion decreases 
exponentially, the red colour neutralizes to white and turns blue as the distance is increased 
either upstream or downstream. The change is more gradual upstream. This may suggest a 
presence of nucleosome in the vicinity.  
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indel freq T C T C C A G C G | G T T C C A T C C T C T A G A G G A T A G A A T G
0 39.8% 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-1 15.6% 0 0 0 0 0 0 0 0 1 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-2 4.9% 0 0 0 0 0 0 0 0 0 | 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-4 3.5% 0 0 0 0 0 0 0 0 0 | 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-3 2.2% 0 0 0 0 0 0 0 0 0 | 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-5 2.2% 0 0 0 0 0 0 0 0 0 | 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
-14 1.0% 0 0 0 0 0 0 0 0 0 | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
|
0 0% 0% 0% 0% 0% 0% 0% 0% 0% | 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-1 0% 0% 0% 0% 0% 0% 0% 0% 16% | 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-2 0% 0% 0% 0% 0% 0% 0% 0% 0% | 5% 5% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-4 0% 0% 0% 0% 0% 0% 0% 0% 0% | 4% 4% 4% 4% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-3 0% 0% 0% 0% 0% 0% 0% 0% 0% | 2% 2% 2% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-5 0% 0% 0% 0% 0% 0% 0% 0% 0% | 2% 2% 2% 2% 2% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-14 0% 0% 0% 0% 0% 0% 0% 0% 0% | 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0% 0% 16% | 14% 14% 9% 7% 3% 1% 1% 1% 1% 1% 1% 1% 1% 1% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
T C T C C A G C G | G T T C C A T C C T C T A G A G G A T A G A A T G
T C T C C A G C - | G T T C C A T C C T C T A G A G G A T A G A A T G
T C T C C A G C G | - - T C C A T C C T C T A G A G G A T A G A A T G
T C T C C A G C G | - - - C C A T C C T C T A G A G G A T A G A A T G
T C T C C A G C G | - - - - C A T C C T C T A G A G G A T A G A A T G
T C T C C A G C G | - - - - - A T C C T C T A G A G G A T A G A A T G
T C T C C A G C G | - - - - - - - - - - - - - - A G G A T A G A A T G
0% 0% 0% 0% 0% 0% 0% 0% 16% | 14% 14% 9% 7% 3% 1% 1% 1% 1% 1% 1% 1% 1% 1% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Figure 20: Heat Map were generated based on the deletion profile. Frequency of 
editing at each base position was calculated.  
Figure 11: The colour scale chart shows how often each base at target site was affected 
by a deletion in control cells and cells treated with each of the five pioneer factors 
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3. MS Excel Regression Analysis 
a. Assumptions 
A simple linear regression model is used to determine the relationship between the distance 
from cut-site of Cas9 endonuclease and the editing frequency. Both these variables are 
considered quantitative variable. The distance from cut-site is considered independent variable 
while the editing frequency calculated as ratio is dependent variable. The distance increases by 
1 base pair from the cut-site (assumed 0 position) in both positive and negative directions. 
This can be observed in figure 22. Additionally, only the distance from positive direction is 
considered in this model. This is in line with the fact that the relationship observes a complex 
trend when both directions are considered. Hence both directions were analyzed separately 
and only the positive direction relationship is included.  
 
 
The mean editing ratio at each base position for all PF types is calculated. A scatter plot is 
created using MS Excel software. For this model, only the distance in positive direction is 
considered. The initial scatter plot exhibits that there is a non-linear relationship between the 
two variables (figure 23). This violates the assumption of a simple linear regression model. 
Simple linear regression model assumes that the relationship between variables is linear. 
Hence, the logarithmic values of mean editing ratios are calculated.  
Figure 22: exponential decrease in editing from cut-site in both directions 
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b. Simple linear regression computation 
A second scatter plot is created using logarithmic values of mean editing ratios and distance 
from cut-site. Using the trendline function of MS Excel graph a best-fit line and its equation 
is generated. The manual calculation (figure 24) using data values include x2, y2, xy, x average 
(xave), y average (yave), predicted y values using best fit line equation (yhat), residual error or 
observed – predicted values (e), sum of error squares (e2). Additionally, model parameters for 
equation b0 and b1, variance in direction of x (SSxx), variation in direction of y (SSyy), 
covariation of x and y (SSxy) are determined. Similarly, Sum of Squares are calculated including 
sum of squares of regression (SSR), residual sum of errors (SSE) and total sum of errors (SST).  
The equations are as follows: 
Yhat =  b0 +  b1x 
b1 =  
SSxy
SSxx
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Figure 23: Initial scatter plot for regression analysis 
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b0 = yave − b1 ∗  xave 
SSyy = ∑(yi − yave)2
n
i=1
 
SSyy = ∑(xi − xave)2
n
i=1
 
SSxy = ∑(xi − xave)(yi − yave)
n
i=1
 
SST =  SSyy 
SSR = b1 ∗ SSxy 
SSE = SST − SSR =  ∑ ei
2
n
i=1
 
 
 
 
 
 
 
 
 
Figure 24: Manual computation of simple linear regression in MS Excel 
  43 
c. Regression statistics 
The regression analysis is conducted using MS Excel Data Analysis tool.  This result (figure 
25) generated by this tool includes the F-test and t-test statistics, coefficient of correlation and 
determination, sum of square of errors, residual output. The results can be used to determine 
the regression model using parameters, and the significance of model and its parameters.  
The regression model of the data is provided in the figure above. The coefficient of correlation 
is 0.97 (97%) suggesting that there is a high correlation between the two variables. The 
coefficient of determination is 0.985 which suggests that about 98.5% of variability of data is 
captured.  
The regression model of the data is provided in the figure above. The coefficient of correlation 
is 0.97 (97%) suggesting that there is a high correlation between the two variables. The 
coefficient of determination is 0.985 which suggests that about 98.5% of variability of data is 
captured.  
The ANOVA section of the result examines the significance of model. The fcritical for given 
degrees of freedom is 4.67. It can be observed that the F-value 423.88 is significantly higher 
than fcritical value. Also, the significance F value 2.63 e -11 is significantly lower than the 
chosen level of significance α = 0.05. Both these results conclude that the model is significant 
or that the significant portion of variability in model is due to relationship of variables. It can 
also be observed that the sum of squares for residual errors is 0.08 which is quite low. 
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The t-test results determining the significance of parameters are provided in the last section. 
The test statistics value is significantly lower than -4, the p-value is significantly lower than the 
chosen level of significance α = 0.05 and the confidence interval does not include 0. The test 
results suggest that both model parameters b0 and b1 are significant. The model using this 
regression analysis tool is -0.64 - 0.10x (figure 26).  
The residual plot (figure 27) is generated using the residual errors and predicted y values. The 
residual plot follows the Ordinary Least Square (OLS) assumptions that errors are 
independent, normally distributed with mean zero and constant variance. The plot and its 
trendline is shown below.  
Figure 25: Regression analysis by MS Excel Data Analysis tool 
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Figure 26: Simple linear regression model 
Figure 27: Residual plot to verify OLS assumption 
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CHAPTER 4 
DISCUSSION 
The results of all experimental procedures including NOME-sequencing, ICE inference, and 
simple linear regression is indicating the presence of nucleosome in the vicinity of Cas9 target 
site.  This is an interesting observation in addition to the proven theory that activated proteins 
or pioneer factors displace nucleosomes leading to chromatin reconfiguration from a closed 
chromatin state to an open chromatin one.  
The NOME-sequencing results would have proved extremely significant to investigate and 
prove this observation. The failure of NOME-sequencing can be attributed to failure of 
bisulfite conversion. The presence of unconverted C residues can be due to errors in 
deamination during bisulfite conversion process (21). Sometimes, during conversion uracil or 
thymine residues may be reconverted to cytosine residues.  
It is very peculiar that unmethylated cytosine residues were not present in all pioneer factor 
treated samples. This is exhibited by the absence of white cells, circles or triangles in grid and 
scale image respectively. The presence of red and black cells suggests that all of GC or GC 
residues were artificially or endogenously methylated. It could be in accordance with the fact 
that pioneer factors managed to displace nucleosome. However, the heat map generated from 
Synthego ICE does not support this conclusion. The heat map shows an exponential decrease 
in editing frequency from the cut-site. The colour of the heat map changes to blue representing 
no editing very quickly. Additionally, the stacked bar chart also shows that the most commonly 
occurred INDELs are 1 or 2 bp long present in the vicinity of cut-site. INDELs with a size 
of more than 21 bp, which may create knockouts, are very rarely observed and that too in one 
of the replicates of the sample. Are these results indicating of a presence of a nucleosome? It 
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may be the case. The simple linear regression analysis results also display a very strong 
relationship between nucleosome position and editing frequency.  
In this case, the images obtained from MEthylviewer for NOME-sequencing were 
reconfigured based on Synthego ICE’s and linear regression data. The sequence of control, 
unedited sample from the ICE software was aligned with the sequence of control sample of 
NOME-sequence. It was observed, that the unedited control sequence of Synthego ICE is 
present on the complementary 3’→5’ strand. After reviewing both sequences simultaneously, 
it was assumed that the nucleosome is preset between 467 and 492 bp. This palindromic 
sequence is shown in figure 28. Hence, NOME-seq images were reanalyzed for positions 467 
to 492 bp. These is the region where nucleosome should have been observed indicated by 
white symbols or cells.  
Figure 28: Expected results for NOME-sequencing. In accordance with Synthego ICE 
result, white cells or circles would have been observed from 467 – 492 bp, indicated as 
nucleosome on top of the image.   
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 These results which indicate the presence of a large protein in the vicinity of target site are 
subsequently suggesting that pioneer factors did not work as expected. However, experimental 
results prove that pioneer factors did elevate editing results. Perhaps, a close inspection should 
be given to the rigid definition of closed and open chromatin. Perhaps pioneer factors 
reconfigured a tightly bound chromatin a loosely bound chromatin. In case of latter DNA is 
still accessible to Cas9 for binding and editing. Another hypothesis is the presence of 
heterochromatin proteins in the vicinity of cut-site. This will also explain the absence of 
unmethylated cytosine residues in NOME-sequencing images.   
Future work can be carried out to prove or disprove these theories. To begin with, NOME-
sequencing can be carried out again for positive results. Another assay to consider is 
Chromatin Immunoprecipitation Sequencing (CHiP-Seq) to determine the presence of 
heterochromatin protein such as HP1 or PERK1 in the region. NOME-seq and CHiP-seq 
assay results can be aligned to determine the presence of proteins and location of nucleosome 
simultaneously giving a broader view of protein-DNA interaction in the vicinity. Cas9 binding 
to chromatin can also be assayed in chromatin treated with pioneer factor to determine if Cas9 
binds effectively to chromatin after treatment. As a control, Cas9 binding to open chromatin 
should also be assayed. Lastly, once the nucleosome is mapped, Cas9 binding at the individual 
sites around nucleosome can be assayed to determine what is impacting Cas9 binding in the 
region.  
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